SGRY Quote, Financials, Valuation and Earnings

Pediatrix Medical Group, Inc. has a net margin of 3.08% compared to Surgery Partners, Inc.'s net margin of 14.55%. Surgery Partners, Inc.'s return on equity of 0.65% beat Pediatrix Medical Group, Inc.'s return on equity of 20.22%.

Surgery Partners, Inc. has a consensus price target of $25.73, signalling upside risk potential of 50.98%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $22.67 which suggests that it could fall by -2.68%. Given that Surgery Partners, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe Surgery Partners, Inc. is more attractive than Pediatrix Medical Group, Inc..

Surgery Partners, Inc. has a beta of 1.932, which suggesting that the stock is 93.198% more volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.766, suggesting its less volatile than the S&P 500 by 23.447%.

Surgery Partners, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

Surgery Partners, Inc. quarterly revenues are $821.5M, which are larger than Pediatrix Medical Group, Inc. quarterly revenues of $492.9M. Surgery Partners, Inc.'s net income of $25.3M is lower than Pediatrix Medical Group, Inc.'s net income of $71.7M. Notably, Surgery Partners, Inc.'s price-to-earnings ratio is -- while Pediatrix Medical Group, Inc.'s PE ratio is 12.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners, Inc. is 0.66x versus 1.04x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of 3.08% compared to Surgery Partners, Inc.'s net margin of -22162.75%. Surgery Partners, Inc.'s return on equity of 0.65% beat Kindly MD, Inc.'s return on equity of -91.57%.

Surgery Partners, Inc. has a consensus price target of $25.73, signalling upside risk potential of 50.98%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 130.2%. Given that Kindly MD, Inc. has higher upside potential than Surgery Partners, Inc., analysts believe Kindly MD, Inc. is more attractive than Surgery Partners, Inc..

Surgery Partners, Inc. has a beta of 1.932, which suggesting that the stock is 93.198% more volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Surgery Partners, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners, Inc. pays -- of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend.

Surgery Partners, Inc. quarterly revenues are $821.5M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. Surgery Partners, Inc.'s net income of $25.3M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, Surgery Partners, Inc.'s price-to-earnings ratio is -- while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners, Inc. is 0.66x versus 15.22x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SRx Health Solutions, Inc. has a net margin of 3.08% compared to Surgery Partners, Inc.'s net margin of -13.47%. Surgery Partners, Inc.'s return on equity of 0.65% beat SRx Health Solutions, Inc.'s return on equity of --.

Surgery Partners, Inc. has a consensus price target of $25.73, signalling upside risk potential of 50.98%. On the other hand SRx Health Solutions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgery Partners, Inc. has higher upside potential than SRx Health Solutions, Inc., analysts believe Surgery Partners, Inc. is more attractive than SRx Health Solutions, Inc..

Surgery Partners, Inc. has a beta of 1.932, which suggesting that the stock is 93.198% more volatile than S&P 500. In comparison SRx Health Solutions, Inc. has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.069%.

Surgery Partners, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SRx Health Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners, Inc. pays -- of its earnings as a dividend. SRx Health Solutions, Inc. pays out -- of its earnings as a dividend.

Surgery Partners, Inc. quarterly revenues are $821.5M, which are larger than SRx Health Solutions, Inc. quarterly revenues of $7.2M. Surgery Partners, Inc.'s net income of $25.3M is higher than SRx Health Solutions, Inc.'s net income of -$964K. Notably, Surgery Partners, Inc.'s price-to-earnings ratio is -- while SRx Health Solutions, Inc.'s PE ratio is 0.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners, Inc. is 0.66x versus 0.07x for SRx Health Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of 3.08% compared to Surgery Partners, Inc.'s net margin of -10.08%. Surgery Partners, Inc.'s return on equity of 0.65% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

Surgery Partners, Inc. has a consensus price target of $25.73, signalling upside risk potential of 50.98%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 111.73%. Given that The Oncology Institute, Inc. has higher upside potential than Surgery Partners, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Surgery Partners, Inc..

Surgery Partners, Inc. has a beta of 1.932, which suggesting that the stock is 93.198% more volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.817%.

Surgery Partners, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners, Inc. pays -- of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend.

Surgery Partners, Inc. quarterly revenues are $821.5M, which are larger than The Oncology Institute, Inc. quarterly revenues of $136.6M. Surgery Partners, Inc.'s net income of $25.3M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, Surgery Partners, Inc.'s price-to-earnings ratio is -- while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners, Inc. is 0.66x versus 0.57x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.